Literature DB >> 17721107

Early virological response of zidovudine/lamivudine/abacavir for patients co-infected with HIV and tuberculosis in Uganda.

Padmini Srikantiah1, Maria N Walusimbi, H Kose Kayanja, Harriet Mayanja-Kizza, Roy D Mugerwa, Royce Lin, Edwin D Charlebois, W Henry Boom, Christopher C Whalen, Diane V Havlir.   

Abstract

Triple nucleoside reverse transcriptase inhibitors are recommended as an alternative regimen for HIV-infected patients undergoing tuberculosis treatment in resource-limited settings. Few data exist on the efficacy of such regimens in tuberculosis patients. In 34 tuberculosis/HIV-co-infected patients treated with zidovudine/lamivudine/abacavir, 76% achieved HIV RNA less than 50 copies/ml at 24 weeks. No cases of hypersensitivity or immune reconstitution syndrome were observed. These data support the continuing evaluation of nucleoside-based antiretroviral regimens as an alternative treatment for this population.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17721107      PMCID： PMC4752198          DOI： 10.1097/QAD.0b013e32823ecf6e

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


  10 in total

1.  Pharmacokinetic interaction between nevirapine and rifampicin in HIV-infected patients with tuberculosis.

Authors:  E Ribera; L Pou; R M Lopez; M Crespo; V Falco; I Ocaña; I Ruiz; A Pahissa
Journal:  J Acquir Immune Defic Syndr       Date:  2001-12-15       Impact factor: 3.731

2.  Population-based hematologic and immunologic reference values for a healthy Ugandan population.

Authors:  Eric S Lugada; Jonathan Mermin; Frank Kaharuza; Elling Ulvestad; Willy Were; Nina Langeland; Birgitta Asjo; Sam Malamba; Robert Downing
Journal:  Clin Diagn Lab Immunol       Date:  2004-01

3.  Initiation of antiretroviral therapy in advanced AIDS with active tuberculosis: clinical experiences from Thailand.

Authors:  S Sungkanuparph; W Manosuthi; S Kiertiburanakul; A Vibhagool
Journal:  J Infect       Date:  2005-06-29       Impact factor: 6.072

4.  Performance of immunologic responses in predicting viral load suppression: implications for monitoring patients in resource-limited settings.

Authors:  David M Moore; Jonathan Mermin; Anna Awor; Benita Yip; Robert S Hogg; Julio S G Montaner
Journal:  J Acquir Immune Defic Syndr       Date:  2006-12-01       Impact factor: 3.731

5.  Plasma nevirapine levels and 24-week efficacy in HIV-infected patients receiving nevirapine-based highly active antiretroviral therapy with or without rifampicin.

Authors:  Weerawat Manosuthi; Somnuek Sungkanuparph; Ammarin Thakkinstian; Sasivimol Rattanasiri; Achara Chaovavanich; Wisit Prasithsirikul; Sirirat Likanonsakul; Kiat Ruxrungtham
Journal:  Clin Infect Dis       Date:  2006-06-12       Impact factor: 9.079

6.  Efavirenz levels and 24-week efficacy in HIV-infected patients with tuberculosis receiving highly active antiretroviral therapy and rifampicin.

Authors:  Weerawat Manosuthi; Somnuek Sungkanuparph; Ammarin Thakkinstian; Asda Vibhagool; Sasisopin Kiertiburanakul; Sasivimol Rattanasiri; Wisit Prasithsirikul; Jongkol Sankote; Apicha Mahanontharit; Kiat Ruxrungtham
Journal:  AIDS       Date:  2005-09-23       Impact factor: 4.177

7.  Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV.

Authors:  Gerald Friedland; Saye Khoo; Christopher Jack; Umesh Lalloo
Journal:  J Antimicrob Chemother       Date:  2006-10-10       Impact factor: 5.790

8.  Diagnostic accuracy of CD4 cell count increase for virologic response after initiating highly active antiretroviral therapy.

Authors:  Gregory P Bisson; Robert Gross; Jordan B Strom; Caitlin Rollins; Scarlett Bellamy; Rachel Weinstein; Harvey Friedman; Diana Dickinson; Ian Frank; Brian L Strom; Tendani Gaolathe; Ndwapi Ndwapi
Journal:  AIDS       Date:  2006-08-01       Impact factor: 4.177

9.  Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection.

Authors:  Roy M Gulick; Heather J Ribaudo; Cecilia M Shikuma; Stephanie Lustgarten; Kathleen E Squires; William A Meyer; Edward P Acosta; Bruce R Schackman; Christopher D Pilcher; Robert L Murphy; William E Maher; Mallory D Witt; Richard C Reichman; Sally Snyder; Karin L Klingman; Daniel R Kuritzkes
Journal:  N Engl J Med       Date:  2004-04-29       Impact factor: 91.245

10.  A pilot study of once-daily antiretroviral therapy integrated with tuberculosis directly observed therapy in a resource-limited setting.

Authors:  Christopher Jack; Umesh Lalloo; Quarraisha Abdool Karim; Salim Abdool Karim; Wafaa El-Sadr; Sharon Cassol; Gerald Friedland
Journal:  J Acquir Immune Defic Syndr       Date:  2004-08-01       Impact factor: 3.731
  10 in total
  7 in total

1.  Biomarkers of HIV Immune Reconstitution Inflammatory Syndrome.

Authors:  Shuli Bonham; David B Meya; Paul R Bohjanen; David R Boulware
Journal:  Biomark Med       Date:  2008       Impact factor: 2.851

2.  A randomized trial of punctuated antiretroviral therapy in Ugandan HIV-seropositive adults with pulmonary tuberculosis and CD4⁺ T-cell counts of ≥ 350 cells/μL.

Authors:  M W Nanteza; H Mayanja-Kizza; E Charlebois; P Srikantiah; R Lin; E Mupere; P Mugyenyi; W H Boom; R D Mugerwa; D V Havlir; C C Whalen
Journal:  J Infect Dis       Date:  2011-09-15       Impact factor: 5.226

3.  Early versus delayed fixed dose combination abacavir/lamivudine/zidovudine in patients with HIV and tuberculosis in Tanzania.

Authors:  Humphrey J Shao; John A Crump; Habib O Ramadhani; Leonard O Uiso; Sendui Ole-Nguyaine; Andrew M Moon; Rehema A Kiwera; Christopher W Woods; John F Shao; John A Bartlett; Nathan M Thielman
Journal:  AIDS Res Hum Retroviruses       Date:  2009-12       Impact factor: 2.205

4.  Expanding antiretroviral options in resource-limited settings--a cost-effectiveness analysis.

Authors:  Eran Bendavid; Robin Wood; David A Katzenstein; Ahmed M Bayoumi; Douglas K Owens
Journal:  J Acquir Immune Defic Syndr       Date:  2009-09-01       Impact factor: 3.731

5.  Unexpected low-level viremia among HIV-infected Ugandan adults with untreated active tuberculosis.

Authors:  Padmini Srikantiah; Joseph K Wong; Teri Liegler; Maria Walusimbi; Harriet Mayanja-Kizza; Harriet K Kayanja; Roy D Mugerwa; Edwin D Charlebois; W Henry Boom; Christopher C Whalen; Diane V Havlir
Journal:  J Acquir Immune Defic Syndr       Date:  2008-12-01       Impact factor: 3.731

6.  Identifying risk factors of immune reconstitution inflammatory syndrome in AIDS patients receiving highly active anti-retroviral therapy.

Authors:  Bo He; Yuhuang Zheng; Meng Liu; Guoqiang Zhou; Xia Chen; Diallo Mamadou; Yan He; Huaying Zhou; Zi Chen
Journal:  Braz J Infect Dis       Date:  2013-02-21       Impact factor: 3.257

Review 7.  Management of HIV-associated tuberculosis in resource-limited settings: a state-of-the-art review.

Authors:  Stephen D Lawn; Graeme Meintjes; Helen McIlleron; Anthony D Harries; Robin Wood
Journal:  BMC Med       Date:  2013-12-02       Impact factor: 8.775
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.